National Pension Service Increases Stake in Alnylam Pharmaceuticals, Inc. $ALNY

National Pension Service raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 198,295 shares of the biopharmaceutical company’s stock after acquiring an additional 14,506 shares during the period. National Pension Service owned approximately 0.15% of Alnylam Pharmaceuticals worth $59,693,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. WINTON GROUP Ltd acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $2,372,000. Engineers Gate Manager LP raised its stake in shares of Alnylam Pharmaceuticals by 3.0% during the 2nd quarter. Engineers Gate Manager LP now owns 33,469 shares of the biopharmaceutical company’s stock worth $10,075,000 after buying an additional 967 shares in the last quarter. NewEdge Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 11.0% during the 2nd quarter. NewEdge Advisors LLC now owns 2,570 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 254 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Alnylam Pharmaceuticals by 5.9% in the 2nd quarter. Arizona State Retirement System now owns 38,025 shares of the biopharmaceutical company’s stock valued at $11,447,000 after buying an additional 2,126 shares during the period. Finally, West Family Investments Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $231,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ALNY shares. HC Wainwright reaffirmed a “buy” rating and set a $455.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 2nd. Oppenheimer decreased their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. TD Cowen reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Bank of America cut their price target on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. Finally, Wells Fargo & Company decreased their price objective on shares of Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a report on Friday, August 14th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $376.67.

Alnylam Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ ALNY opened at $248.68 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a market capitalization of $33.28 billion, a PE ratio of 46.22 and a beta of 0.31. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The firm’s 50-day moving average is $254.43 and its two-hundred day moving average is $288.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period last year, the company posted ($0.51) EPS. The company’s revenue was up 66.9% on a year-over-year basis. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).